Strategic report Directors report Risk review and capital review Financial statements Supplementary information Company balance sheet As at 31 December 2018 31.12.18 31.12.17 Notes $million $million Non-current assets Investments in subsidiary undertakings 32 34,853 34,853 Current assets Derivative financial instruments 39 9 70 Investment securities 39 11,537 12,159 Amounts owed by subsidiary undertakings 39 17,606 15,714 Taxation 12 3 Total current assets 29,164 27,946 Current liabilities Derivative financial instruments 39 1,128 492 Other creditors 403 405 Total current liabilities 1,531 897 Net current assets 27,633 27,049 Total assets less current liabilities 62,486 61,902 Non-current liabilities Debt securities in issue 39 17,202 16,169 Subordinated liabilities and other borrowed funds 27, 39 13,436 13,882 Total non-current liabilities 30,638 30,051 Total assets less liabilities 31,848 31,851 Equity Share capital and share premium account 28 7,111 7,097 Other reserves 17,129 17,129 Retained earnings 2,647 2,664 Total shareholders equity 26,887 26,890 Other equity instruments 28 4,961 4,961 Total equity 31,848 31,851 The Company has taken advantage of the exemption in section 408 of the Companies Act 2006 not to present its individual statement of comprehensive income and related notes that form a part of these financial statements.
The Company profit for the year after tax is $799 million 31 December 2017: $210 million.
The Notes on pages 244 to 355 form an integral part of these financial statements.
These financial statements were approved by the Board of directors and authorised for issue on 26 February 2019 and signed on its behalf by: Jos Vials Bill Winters Andy Halford Chairman Group Chief Executive Group Chief Financial Officer 241
